{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:07Z","timestamp":1786979887117,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-FAPI (fibroblast activation protein inhibitor) is a rapidly evolving and highly promising radiotracer for PET\/CT imaging, presenting excellent results in a variety of tumor entities, particularly in epithelial carcinomas. This retrospective analysis sought to evaluate the potential and impact of FAPI-PET\/CT in rare cancer diseases with respect to improvement in staging and therapy, based on tracer uptake in normal organs and tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      Fifty-five patients with rare tumor entities, defined by a prevalence of 1 person out of 2000 or less, received a\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-FAPI-PET\/CT scan. Fourteen women and 41 men (median age 60) were included within the following subgroups: cancer of unknown primary (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910), head and neck cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913), gastrointestinal and biliary-pancreatic cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917), urinary tract cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), neuroendocrine cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), and others (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). Tracer uptake was quantified by standardized uptake values SUVmax and SUVmean and the tumor-to-background ratio (TBR) was determined (SUVmax tumor\/SUVmean organ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 20 out of 55 patients, the primary tumor was identified and 31 patients presented metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200988), characterized by a high mean SUVmax in primary (10.1) and metastatic lesions (7.6). The highest uptake was observed in liver metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) with a mean SUVmax of 9.8 and a high TBR of 8.7, closely followed by peritoneal carcinomatosis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) presenting a mean SUVmax of 9.8 and an excellent TBR of 29.6. In terms of the included subgroups, the highest uptake regarding mean SUVmax was determined in gastrointestinal and biliary-pancreatic cancer with 9.8 followed closely by urinary tract cancer with 9.5 and head and neck cancer (9.1).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Due to excellent tumor visualization and, thereby, sharp contrasts in terms of high TBRs in primary and metastatic lesions in different rare malignancies,\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-FAPI-PET\/CT crystallizes as a powerful and valuable imaging tool, particularly with respect to epithelial carcinomas, and therefore an enhancement to standard diagnostics imaging methodologies. The realization of further and prospective studies is of large importance to confirm the potential of FAP imaging in oncology.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-021-05488-9","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T04:03:24Z","timestamp":1627963404000},"page":"721-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["FAP imaging in rare cancer entities\u2014first clinical experience in a broad spectrum of malignancies"],"prefix":"10.1007","volume":"49","author":[{"given":"K.","family":"Dendl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Finck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"R\u00f6hrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rathke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gampp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ristau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"5488_CR1","unstructured":"Rare diseases I European Commission (Europa.eu);\u00a0https:\/\/ec.europa.eu\/info\/research-and-innovation\/research-area\/health-research-and-innovation\/rare-diseases.\u00a0Accessed March 2021."},{"issue":"6","key":"5488_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, R\u00f6hrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, J\u00e4ger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"issue":"10","key":"5488_CR3","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marm\u00e9 F, J\u00e4ger D, Mier W, Haberkorn U. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"key":"5488_CR4","doi-asserted-by":"crossref","unstructured":"Dendl K, Koerber SA, Finck R, Mokoala K, Staudinger F, Schillings L, Heger U, R\u00f6hrich M, Kratochwil C, Sathekge M, J\u00e4ger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05378-0.","DOI":"10.1007\/s00259-021-05378-0"},{"issue":"9","key":"5488_CR5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2016","unstructured":"Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002\u201319. https:\/\/doi.org\/10.1101\/gad.279737.116.","journal-title":"Genes Dev"},{"key":"5488_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ceb.2018.09.002","volume":"56","author":"J Barbaz\u00e1n","year":"2019","unstructured":"Barbaz\u00e1n J, Matic VD. Cancer associated fibroblasts: is the force the path to the dark side? Curr Opin Cell Biol. 2019;56:71\u20139. https:\/\/doi.org\/10.1016\/j.ceb.2018.09.002.","journal-title":"Curr Opin Cell Biol"},{"issue":"18","key":"5488_CR7","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235\u20139. https:\/\/doi.org\/10.1073\/pnas.87.18.7235.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5488_CR8","doi-asserted-by":"publisher","first-page":"100226","DOI":"10.1016\/j.jhepr.2021.100226","volume":"3","author":"A Moeini","year":"2021","unstructured":"Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021;3(2):100226. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100226.","journal-title":"JHEP Rep"},{"issue":"6","key":"5488_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s0027-9684(15)31343-2","volume":"100","author":"BF Adeyemi","year":"2008","unstructured":"Adeyemi BF, Adekunle LV, Kolude BM, Akang EE, Lawoyin JO. Head and neck cancer\u2013a clinicopathological study in a tertiary care center. J Natl Med Assoc. 2008;100(6):690\u20137. https:\/\/doi.org\/10.1016\/s0027-9684(15)31343-2.","journal-title":"J Natl Med Assoc"},{"key":"5488_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05146-6","author":"L Zhao","year":"2021","unstructured":"Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, Sun L, Wu H, Lin Q, Chen H. Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-020-05146-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5488_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05307-1","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, Sennung D, Roehrich M, Debus J, Sathekge M, Haberkorn U, Calais J, Serfling S, Buck AL. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05307-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5488_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J\u00e4ger D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.215913.","journal-title":"J Nucl Med"},{"issue":"8","key":"5488_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61(8):1171\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.236786.","journal-title":"J Nucl Med"},{"issue":"2","key":"5488_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jim\u00e9nez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, R\u00f6hrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C. FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.245084.","journal-title":"J Nucl Med"},{"issue":"9","key":"5488_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, J\u00e4ger D, Mier W, Haberkorn U. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"5488_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05095-0","author":"W Guo","year":"2020","unstructured":"Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-05095-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5488_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-021-00353-y","volume":"8","author":"BK Geist","year":"2021","unstructured":"Geist BK, Xing H, Wang J, Shi X, Zhao H, Hacker M, Sang X, Huo L, Li X. A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET\/CT imaging. EJNMMI Phys. 2021;8(1):8. https:\/\/doi.org\/10.1186\/s40658-021-00353-y.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"5488_CR18","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/hep.26762","volume":"59","author":"AE Sirica","year":"2014","unstructured":"Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2014;59(6):2397\u2013402. https:\/\/doi.org\/10.1002\/hep.26762.","journal-title":"Hepatology"},{"issue":"12","key":"5488_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","volume":"21","author":"Y Lin","year":"2019","unstructured":"Lin Y, Li B, Yang X, Cai Q, Liu W, Tian M, Luo H, Yin W, Song Y, Shi Y, He R. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia. 2019;21(12):1133\u201342. https:\/\/doi.org\/10.1016\/j.neo.2019.10.005.","journal-title":"Neoplasia"},{"issue":"1","key":"5488_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/cancers5010149","volume":"5","author":"S Togo","year":"2013","unstructured":"Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel). 2013;5(1):149\u201369. https:\/\/doi.org\/10.3390\/cancers5010149.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5488_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, Hern\u00e1ndez V, Linares Espin\u00f3s E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskim\u00e4e E, Ribal MJ, van der Heijden AG. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"issue":"21","key":"5488_CR22","doi-asserted-by":"publisher","first-page":"00029","DOI":"10.1016\/j.euo.2021.01.005","volume":"S2588\u20139311","author":"CS Voskuilen","year":"2021","unstructured":"Voskuilen CS, van Gennep EJ, Einerhand SMH, Vegt E, Donswijk ML, Bruining A, van der Poel HG, Horenblas S, Hendricksen K, van Rhijn BWG, Mertens LS. Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer. Eur Urol Oncol. 2021;S2588\u20139311(21):00029\u201338. https:\/\/doi.org\/10.1016\/j.euo.2021.01.005.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"5488_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000497355","volume":"109","author":"M Cives","year":"2019","unstructured":"Cives M, Pelle\u2019 E, Quaresmini D, Rizzo FM, Tucci M, Silvestris F. The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications. Neuroendocrinology. 2019;109(2):83\u201399. https:\/\/doi.org\/10.1159\/000497355.","journal-title":"Neuroendocrinology"},{"issue":"24","key":"5488_CR24","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1002\/cncr.31079","volume":"123","author":"FM Laskaratos","year":"2017","unstructured":"Laskaratos FM, Rombouts K, Caplin M, Toumpanakis C, Thirlwell C, Mandair D. Neuroendocrine tumors and fibrosis: an unsolved mystery? Cancer. 2017;123(24):4770\u201390. https:\/\/doi.org\/10.1002\/cncr.31079.","journal-title":"Cancer"},{"key":"5488_CR25","doi-asserted-by":"publisher","unstructured":"Wang H, Du Z, Huang Q, Ren S, Guan Y, Xie F, Lu L, Zhu W. The superiority of [68Ga]Ga-FAPI-04 over [18F]-FDG in a case of neuroendocrine tumour with hepatic metastasis. Eur J Nucl Med Mol Imaging. 2021 Feb 23. https:\/\/doi.org\/10.1007\/s00259-021-05247-w","DOI":"10.1007\/s00259-021-05247-w"},{"key":"5488_CR26","doi-asserted-by":"publisher","unstructured":"K\u00f6mek H, G\u00fcndo\u011fan C, Can C. 68Ga-FAPI PET\/CT versus 68Ga-DOTATATE PET\/CT in the evaluation of a patient with neuroendocrine tumor. Clin Nucl Med. 2020 Dec 21;Publish Ahead of Print. https:\/\/doi.org\/10.1097\/RLU.0000000000003490","DOI":"10.1097\/RLU.0000000000003490"},{"issue":"12","key":"5488_CR27","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","volume":"47","author":"M Syed","year":"2020","unstructured":"Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, Koerber SA, Freudlsperger C, Plinkert PK, Debus J, Giesel F, Haberkorn U, Adeberg S. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47(12):2836\u201345. https:\/\/doi.org\/10.1007\/s00259-020-04859-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5488_CR28","doi-asserted-by":"publisher","unstructured":"Kratochwil C, Giesel FL, Rathke H, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma [published online ahead of print, 2021 Mar 17].\u00a0Eur J Nucl Med Mol Imaging. 2021;https:\/\/doi.org\/10.1007\/s00259-021-05273-8.","DOI":"10.1007\/s00259-021-05273-8"},{"issue":"6","key":"5488_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA. International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and definitions-a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906\u201314. https:\/\/doi.org\/10.1016\/j.jval.2015.05.008.","journal-title":"Value Health"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05488-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T01:24:41Z","timestamp":1660353881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05488-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5488"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05488-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-359270\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"UH, TL, CK, WM, and FLG have a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. UH, TL, CK, and FLG also have shares of a consultancy group for iTheranostics. FLG is a medical advisor for ABX Advanced Biochemical Compound, Telix Pharmaceuticals, and SOFIE Biosciences. JD reports grants from ViewRay Inc., grants from CRI The Clinical Research Institute GmbH, grants from Accuray International Sarl, grants from RaySearch Laboratories AB, grants from Vision RT Limited, grants from Merck Serono GmbH, grants from Astellas Pharma GmbH, grants from Astra Zeneca GmbH, grants from Siemens Healthcare GmbH, grants from Solution Akademie GmbH, grants from Ergomed PLC Surrey Research Park, grants from Quintiles GmbH, grants from Pharmaceutical Research Associates GmbH, grants from Boehringer Ingelheim Pharma GmbH & Co. KG, grants from PTW-Freiburg Dr. Pychlau GmbH, grants from Nanobiotix S.A, outside the submitted work. SAK reports grants from ViewRay Inc., outside the submitted work. SA received grants from Accuray International Sarl, Merck Serono GmbH, Astra Zeneca GmbH, MSD,\u00a0and Novocure GmbH outside the submitted work. S.A. holds shares from Novocure GmbH, Actinium Pharmaceuticals, Chimerix Inc., Telix Pharmaceuticals, and Clovis Oncology. All other authors declare no potential conflicts of interest relevant to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}